U.C.A. Aktiengesellschaft
U.C.A. AG english
Corpoprate-news transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
Trade sale of the 50 % investment in the BioMed Venture AG
Strategic termination of the business sector Biotech/Life Science
Concentration on the area of high tech engineering
October 8th, 2001, Munich
U.C.A. is selling its 50 % share in the BioMed Venture AG to the
“Kreissparkasse” in Hanover, one of the large institutes within the association
of savings banks. In the future, U.C.A. will no longer directly invest in
Biotech- and Life Science start-ups. With this step, U.C.A. consciously pulls
out of financing fledgling companies in this sector because it appears to make
sense for U.C.A. that large financial groups and industrial partners assume
this role due to the long development cycles and corresponding high
prefinancing payments.
The increased concentration on investment areas such as micro systems
technology, nano technology, sensory analysis and optoelectronics, classical
German high tech engineering sectors with intelligible finance requirements in
time periods which can be planned is U.C.A.’s answer to the increasing demand
for promising investments in the VC area. With 10 investments, U.C.A. is
already represented in these areas.
The Managing Board
Contact:
Investor Relations
Daniel Schirok
Tel. : + 49 (0) 89 – 99 31 94-36
e-mail : investor.relations@uca.de
end of announcement (c)DGAP 08.10.2001
——————————————————————————–
WKN: 701200; Index:
Listed: Freiverkehr in Berlin, Düsseldorf, Frankfurt, Hamburg, München
(Prädikatsmarkt) und Stuttgart
082015 Okt 01
Aktuelle News
Aktuelle Berichte
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden